Teva, Protalix to collaborate on two proteins

By Lisa Kerner

Charlotte, N.C., Sept. 26 - Teva Pharmaceutical Industries Ltd. signed a collaboration and licensing agreement with Protalix Biotherapeutics Ltd. to develop two undisclosed proteins using Protalix's plant cell culture technology.

Under the agreement, Teva will be granted an exclusive license to commercialize the developed products in exchange for royalty and milestone payments to Protalix.

Protalix, a Carmiel, Israel biopharmaceutical company, retains certain exclusive manufacturing rights.

Teva is a Petach Tikva, Israel, pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.